Cathie Wood’s ARK Invest Buys Over 170,000 Shares of Pfizer
One of Cathie Wood's ARK Invest exchange-traded funds bought over 170,000 shares of Pfizer on August 26.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
One ARK Invest exchange-traded fund run by ETF star Cathie Wood bought over 170,000 shares of Pfizer Inc. (NYSE: PFE | PFE Price Prediction) on Thursday, as the price of this fund was down over 1% in the day’s session. It is still up a fair amount in the past year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) added 173,579 shares of Pfizer. At Thursday’s closing price, this would have valued this purchase at roughly $8.2 million. This is only a small fraction of the total holdings. The fund is up 36% over the past 52 weeks.
Check out all the ARK Invest buys for Thursday:
| Fund | Ticker | Name | Shares |
|---|---|---|---|
| ARKF | PDD | PINDUODUO | 59,300 |
| ARKF | COIN | COINBASE GLOBAL | 7,054 |
| ARKG | RPTX | REPARE THERAPEUTICS | 2,468 |
| ARKG | QSI | QUANTUM-SI | 34,201 |
| ARKG | PSNL | PERSONALIS | 40,468 |
| ARKG | PFE | PFIZER | 173,579 |
| ARKG | MASS | 908 DEVICES | 25,000 |
| ARKG | DYNS | DYNAMICS SPECIAL PURPOSE | 1,696 |
| ARKG | ADPT | ADAPTIVE BIOTECHNOLOGIES | 62,252 |
| ARKG | BEAM | BEAM THERAPEUTICS | 17,033 |
| ARKG | CMIIU | CM LIFE SCIENCES II | 25,000 |
| ARKK | VCYT | VERACYTE | 26,653 |
| ARKK | NVTA | INVITAE | 319,045 |
| ARKK | SGFY | SIGNIFY HEALTH | 178,955 |
| ARKK | FATE | FATE THERAPEUTICS | 60,075 |
| ARKQ | KTOS | KRATOS DEFENSE & SECURITY SOLUTIONS | 201,508 |
| ARKQ | KMTUY | KOMATSU | 21,700 |
| ARKQ | AVAV | AEROVIRONMENT | 8,767 |
| ARKQ | ACIC | ATLAS CREST INVESTMENT | 460,000 |
| ARKW | SPLK | SPLUNK | 116,466 |
| ARKW | LPSN | LIVEPERSON | 23,856 |
| ARKW | GENI | GENIUS SPORTS | 135,457 |
| ARKX | PRNT | 3D PRINTING ETF | 12,670 |
[nativounit]
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
[recirclink id=942416][wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
